Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer's Disease
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 31/03/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimers disease. ANAVEX 2-73 is the first of a new
Abstract: Hoboken, NJ March 31, 2011 -- Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimers disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonism as well as muscarinic cholinergic effects and up-regulation of Bcl-2. ANAVEX 2-73 also modulates endoplasmic reticu...
To read the full release go to http://www.sources.com/Releases/NR1214.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.